Yazar "Sarin, Shiv K." için listeleme
-
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Eslam, Mohammed; Fan, Jian-Gao; Yu, Ming-Lung; Wong, Vincent Wai-Sun; Cua, Ian Homer; Liu, Chun-Jen; Tanwandee, Tawesak; Gani, Rino; Seto, Wai-Kay; Alam, Shahinul; Young, Dan Yock; Hamid, Saeed; Zheng, Ming-Hua; Kawaguchi, Takumi; Chan, Wah-Kheong; Payawal, Diana; Tan, Soek-Siam; Goh, George Boon-bee; Strasser, Simone I.; Viet, Hang Dao; Kao, Jia-Horng; Kim, Won; Kim, Seung Up; Keating, Shelley E.; Yılmaz, Yusuf; Kamani, Lubna; Wang, Chia-Chi; Fouad, Yasser; Abbas, Zaigham; Treeprasertsuk, Sombat; Thanapirom, Kessarin; Al Mahtab, Mamun; Lkhagvaa, Undram; Baatarkhuu, Oidov; Choudhury, Ashok Kumar; Stedman, Catherine A. M.; Chowdhury, Abhijit; Dökmeci, A Kadir; Wang, Fu-Sheng; Lin, Han-Chieh; Huang, Jee-Fu; Howell, Jess; Jia, Jidong; Alboraie, Mohamed; Roberts, Stuart K.; Yoneda, Masato; Ghazinian, Hasmik; Mirijanyan, Aram; Nan, Yuemin; Lesmana, Cosmas Rinaldi Adithya; Adams, Leon A.; Shiha, Gamal; Kumar, Manoj; Örmeci, Necati; Wei, Lai; Lau, George; Omata, Masao; Sarin, Shiv K.; George, Jacob (Springer, 2025)Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for ... -
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Anstee, Quentin M.; Lucas, Kathryn J.; Francque, Sven; Abdelmalek, Manal F.; Sanyal, Arun J.; Ratziu, Vlad; Gadano, Adrian C.; Rinella, Mary; Charlton, Michael; Loomba, Rohit; Mena, Edward; Schattenberg, Jörn M.; Noureddin, Mazen; Lazas, Donald; Goh, George B.B.; Sarin, Shiv K.; Yılmaz, Yusuf; Martic, Miljen; Stringer, Rowan; Kochuparampil, Jossy; Chen, Li; Rodriguez-Araujo, Gerardo; Chng, Elaine; Naoumov, Nikolai V.; Brass, Clifford; Pedrosa, Marcos C. (Wolters Kluwer Medknow Publications, 2023)Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study ...
